Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.54 |
| ▸ | FNTA | P49354 | 5/20 | 0.41 |
| ▸ | FNTB | P49356 | 5/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163166 | 0.99 | CYP11B1 (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL8005944 | 0.87 | CYP11B1 (0.56) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7194363 | 0.85 | CYP11B1 (0.57) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7654511 | 0.84 | CYP11B1 (0.51) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL7629321 | 0.83 | CYP11B1 (0.45) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL7574960 | 0.82 | CYP11B1 (0.49) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL3625451 | 0.82 | CYP11B1 (0.77) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7704743 | 0.82 | CYP11B1 (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7263769 | 0.82 | CYP11B1 (0.42) | CYP11B1CYP11B2CACNA1H | |
| SCHEMBL6452310 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090012-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6410534-B1 | ANTICANCER AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1165082-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6387903-B1 | ANTICANCER AGENT; CARDIOVASCULAR DISORDERS; VIRICIDES | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020052380-A1 | Inhibitors of prenyl-protein transferase | DINSMORE CHRISTOPHER J (US) | 2002-05-02 | — | — | US | disclosed |
| US-6358985-B1 | ANTICANCER AGENT | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| US-20020022633-A1 | Inhibitors of prenyl-protein transferase | WILLIAMS THERESA M (US) | 2002-02-21 | — | — | US | disclosed |
| US-20020010184-A1 | Inhibitors of prenyl-protein transferase | DINSMORE CHRISTOPHER J (US) | 2002-01-24 | — | — | US | disclosed |
| WO-2002002108-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1165082-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1091736-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-1090012-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2001017992-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000051611-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-1014984-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000001382-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999009985-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010184-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, ZMPSTE24 | CYP11B1 2931/4885CYP11B2 3762/4885FNTA 1/4885 |
| US-20020022633-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, FNTB | CYP11B1 1882/4885CYP11B2 2516/4885FNTA 1/4885 |
| US-20020052380-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, GGPS1 | CYP11B1 1109/4885CYP11B2 1821/4885FNTA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.